- Joseph Loscalzo, M.D., Ph.D
Harvard Medical School - Augustine Choi, M.D.
Harvard Medical School - Michael Marletta, Ph.D
Scripts Research Institute - Jan Wasley, Ph.D
Simpharma, LLC
Joseph Loscalzo, M.D., Ph.D
Hersey Professor of the Theory and Practice of Medicine Harvard Medical School,
Physician-in-Chief Brigham and Woman’s Hospital,
Editor-in-Chief Circulation
Dr. Joseph Loscalzo is a Director and Chairman of the Scientific Advisory Board of N30 Pharmaceuticals.
Dr. Loscalzo was the Co-Founder, Director, and Chairman of the Scientific Advisory Board of NitroMed, Inc. He is a Member of the Scientific Advisory Board at CB Health Ventures, L.L.C., Excel Medical Ventures, and Mi3 Ventures Partners. He also served as a Member of the Scientific and Clinical Advisory Committee of Adherex Technologies Inc.
Dr. Loscalzo is the Wade Professor and Professor of Biochemistry, Chairman of the Department of Medicine since 1997, and Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine. He joined the faculty of Boston University in 1994 as Chief of Cardiology. Dr. Loscalzo is also the Physician-in-Chief at Boston Medical Center.
In 2004, Dr. Loscalzo became Editor-in-Chief of Circulation. Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He ultimately rose to the rank of Associate Professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and Director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital.
Dr. Loscalzo is a Director of the Whitaker Cardiovascular Institute at Boston University School of Medicine. He is a Director of the NIH-sponsored Specialized Center for Research in Ischemic Heart Disease at Boston University and the Chairman of the Executive Committee of the NIH-sponsored Cardiovascular Proteomics Center at Boston University.
Dr. Loscalzo has served on several NIH study sections and editorial boards, including serving as past Associate Editor of the New England Journal of Medicine and has chaired the Gordon Conference on Thrombolysis. Dr. Loscalzo is the immediate past Chair of the Cardiovascular Board of the American Board of Internal Medicine and immediate past Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the NIH.
Dr. Loscalzo has authored and co-authored more than 400 scientific publications and 20 books. He is also the recipient of many grants from the NIH and industry for his work in the areas of vascular biology, thrombosis, and atherosclerosis over the past 20 years.
Dr. Loscalzo has received many awards including the Clinician-Scientist Award and the Distinguished Scientist Award of the American Heart Association, the Research Career Development Award of the NIH, the George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital, Educator of the Year Award in Clinical Medicine at Boston University, the Glaxo Cardiovascular Research Award, and election to the prestigious American Society for Clinical Investigation and Association of American Physicians.
Dr. Loscalzo’s training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiology. Dr. Loscalzo received a Ph.D. in Biochemistry, a M.D. from the University of Pennsylvania, and an A.B. degree, summa cum laude.
Augustine Choi, M.D.
Parker B. Francis Professor and Chief of Pulmonary and Critical Care Medicine,
Brigham and Women’s Hospital and Harvard School of Medicine
Dr. Choi is the point person for the Center for Integration of Medicine
and Innovative Technology (CIMIT) Inhalation Technology Program. He currently is Chief, Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital.
Previously Dr. Choi was at the University of Pittsburgh, Yale and Johns Hopkins. His lab has made seminal observations that inhaled CO can confer cytoprotection in preclinical models of lung diseases.
Michael Marletta, Ph.D
President and CEO, Cecil H. and Ida M. Green Professor of Chemistry, The Scripps Research Institute
Dr. Marletta is a member of the American Chemical Society and the American Society for Biochemistry and Molecular
Biology. He currently serves on the Board of Editors of ACS Chemical Biology and on the editorial board of
PNAS as well as a number of other journals.
Dr. Marletta is a consultant for a number of pharmaceutical companies and has served on the scientific advisory boards of NitroMed, Inc. and Oxon Medica, Inc. He is a co-founder of Omniox, Inc.
He is a member of the Fredonia College Foundation Board of Directors. In 2008 he was appointed to the HHMI Science Advisory Board.
Jan Wasley, Ph.D
Simpharma
Dr. Wasley has over 40 years experience in the design, discovery and development of novel drugs for a wide variety of diseases, and has over 90 publications and patents in the area of medicinal chemistry.
Dr. Wasley has discovered/developed more than 25 drugs that have reached advanced clinical or preclinical development status including Aptazapine (alpha-2 adrenergic selective antagonist – for depression, Serazapine (5-HT2 selective antagonist – for anxiety) and Zaldaride (a specific calmodulin inhibitor – for GI secretory diseases such as diarrhea).
Dr. Wasley has also discovered and developed clinical candidate dugs in the areas of rheumatoid arthritis, osteoarthritis, allergy, cancer and CNS disorders such as depression, schizophrenia and anxiety and cognitive disorders.
Dr. Wasley retired in 2001, but has remained active as a founder of SimPharma LLC, where he developed instructional tools for drug discovery and has been teaching drug design, discovery and development courses at the University of Connecticut and Wesleyan University.